Mobile

A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Reactogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Ambulatory Elderly Adults Aged 68 Years and Older Who R...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-002683-10

A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Reactogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Ambulatory Elderly Adults Aged 68 Years and Older Who Received 1 or More Doses of 23-valent Pneumococcal Polysaccharide Vaccine at Least 3 Years Before Study Enrollment

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the acceptability of the safety profile of a single injection of 13vPnC administered at least 3 years after 1 or more nonstudy doses of 23vPS as measured by the incidence rates of local reactions, systemic events, and adverse events.

Critère d'inclusion

  • Pneumococcal infection

Liens